Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 9/20 | 0.60 |
| ▸ | GABRD | O14764 | 9/20 | 0.60 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.60 |
| ▸ | GABRB1 | P18505 | 9/20 | 0.60 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.60 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.60 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.60 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.60 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.60 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.60 |
| ▸ | GABRA4 | P48169 | 9/20 | 0.60 |
| ▸ | GABRE | P78334 | 9/20 | 0.60 |
| ▸ | GABRA6 | Q16445 | 9/20 | 0.60 |
| ▸ | GABRG1 | Q8N1C3 | 9/20 | 0.60 |
| ▸ | GABRG3 | Q99928 | 9/20 | 0.60 |
| ▸ | GABRQ | Q9UN88 | 9/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | TNKS | O95271 | 1/20 | 0.57 |
| ▸ | NQO1 | P15559 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31217580 | 0.85 | MAOB (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL266614 | 0.81 | MAPT (0.63) | ACHENQO1KDM4ETP53MAPT | |
| SCHEMBL27821368 | 0.78 | ADCY1 (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22950970 | 0.78 | CSNK2A2 (0.62) | ACHEMAOBCYP1A2KDM4ELMNA | |
| SCHEMBL13978681 | 0.78 | TP53 (0.61) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17786615 | 0.78 | EGFR (0.60) | ACHECYP1A2KDM4ELMNATP53 | |
| SCHEMBL21591565 | 0.77 | ACHE (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9976084 | 0.75 | ACHE (0.68) | ACHENQO1MAOBKDM4ELMNA | |
| SCHEMBL8193938 | 0.75 | GABRP (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9431755 | 0.75 | STS (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| EP-2102196-B1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM SPA (IT) | 2012-08-01 | — | — | EP | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8058447-B2 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8003810-B2 | Process for preparing Nebivolol | ZACH SYSTEM S.P.A. (IT) | 2011-08-23 | — | — | US | disclosed |
| US-8003810-B2 | Process for preparing Nebivolol | ZACH SYSTEM S.P.A. (IT) | 2011-08-23 | — | — | US | disclosed |
| US-20100076206-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20100076206-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| WO-2008064826-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076206-A1 | PROCESS FOR PREPARING NEBIVOLOL | ADRB1, ADRB2, ADRA1B | GABRP 1901/4885GABRD 2234/4885GABRA1 1806/4885 |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | RYR1, TNNI3, RYR2 | GABRP 3256/4885GABRD 2452/4885GABRA1 3040/4885 |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | GABRP 1127/4885GABRD 1359/4885GABRA1 762/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | GABRP 1413/4885GABRD 1577/4885GABRA1 680/4885 |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | CCNK, CDK3, CCNO | GABRP 3949/4885GABRD 3171/4885GABRA1 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.